Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2013

View Archived Issues

Nintedanib shows no activity against recurrent high-grade gliomas

Phase II trial planned after phase I study completed with selumetinib in children with gliomas

Bispecific hexavalent antibody shows promise for treating lupus

ImmunoCellular Therapeutics reports phase II data for ICT-107

Integral Molecular generates MAbs against the P2X3 ion channel

KaloBios Pharmaceuticals presents phase I results for KB-004

AGI-14100 significantly reduces tumor burden in IDH1-mutant mouse model

Swiss group discloses new MPC modulators

Convergence Pharmaceuticals prepares novel sodium channel blockers for pain

New potassium channel modulators patented by Autifony Therapeutics

Piramal Enterprises synthesizes new pyrimidine compounds

Korean researchers present new antibodies that bind to RANKL for bone disorders

Mallinckrodt completes clinical trials of MNK-155

Novel Trk-A inhibitors designed by Merck & Co.

SPX-106T lowers cholesterol and triglyceride levels and prevents weight gain in vivo

Canadian approval for Lemtrada

FDA advisory committee votes in favor of Oralair for grass pollen allergy

Stem cell candidate receives orphan drug designation in Japan

FDA advisory committee recommends approval of dapagliflozin

Celator's phase III study of CPX-351 for AML cleared to continue by DSMB

CDRD Ventures launches spin-off company Kairos Therapeutics

Dementia Consortium launched in the UK to advance drug development

FDA approves Complera for patients with HIV switching from a stable regimen

Endocyte begins phase I study of EC-1456 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...